期刊文献+

多药耐药相关蛋白在肝癌耐药细胞系HepG2/Oxal中的作用机制研究 被引量:3

Role of multi-drug resistance proteins in drug resistance cell line HepG2/Oxal of hepatocellular carcinoma
下载PDF
导出
摘要 目的:探讨多药耐药(multi-drug resistance,MDR)相关蛋白在肝癌细胞系HepG2及不同浓度耐奥沙利铂(oxaliplatin,Oxal)亚系中的表达及参与肝癌对Oxal耐药的机制。方法:以浓度递增法诱导肝癌细胞系HepG2,建立2.5、5.0μg/ml的Oxal耐药亚系,以半定量RT-PCR法测定MDR、多药耐药相关蛋白(multi-drug resistance related protein,MRP)和乳腺癌耐药蛋白(breast cancer resistance protein,BCRP)在亲代和不同耐药亚系中的mRNA表达,并在蛋白水平以Western blot法验证基因表达的差异性。结果:成功建立了IC50值为15和25倍亲代细胞的Oxal耐药亚系(HepG2/Oxal);在mRNA和蛋白水平,BCRP的表达与HepG2的耐药性呈正相关,而MDR、MRP的表达在耐药的早期升高不明显,随着耐药程度的增加其表达增加。结论:BCRP在HepG2对Oxal获得性耐药中起着重要作用,MDR和MRP在HepG2/Oxal耐药过程中早期起的作用不明显,随着耐药浓度的增加,表达越来越高。 Objective:To investigate the expression of multi-drug resistance-associated proteins(MDR) in Hepatocellular cancer cell line HepG2 and in different concentrations of sub-cell line of oxaliplatin(Oxal),and to study the mechanism of their resistance to Oxal.Methods:HepG2 multi-drug resistance sub-cell line was induced by increasing the concentration of Oxal progressively,and the drug resistance cell line 2.5 μg/ml HepG2/Oxal and 5.0 μg/ml HepG2/Oxal was successfully established.The mRNA expression of the MDR,the expression of multi-drug resistance related protein(MRP) and breast cancer resistance protein(BCRP) in the cell lines(HepG2/Oxal) of 2.5 μg/ml HepG2/Oxal and 5.0 μg/ml HepG2/Oxal were detected using RT-PCR,and the variability of the gene expression was verified by Western blot.Results:HepG2/Oxal drug resistance cell subseries with IC50 value of 15 and 25 times were successfully constructed.BCRP expression was positively correlated with HepG2 drug resistance at mRNA and the protein level.But MDR and MRP did not display significant high expression in the prophase drug resistance subseries;the expression of MDR and MRP increased along with the rise of drug resistance level.Conclusions:BCRP plays an important role in the acquired character resistance of HepG2 cell line to Oxal;the expression of MDR and MRP is not obvious at the prophase of the resistance,but increases with the rise of the resistance level.
出处 《蚌埠医学院学报》 CAS 2011年第1期11-14,共4页 Journal of Bengbu Medical College
关键词 肝肿瘤 奥沙利铂 多药耐药蛋白 乳腺癌耐药蛋白 liver neoplasms oxaliplatin multi-drug resistance protein breast cancer resistance protein
  • 相关文献

参考文献5

二级参考文献52

共引文献24

同被引文献70

  • 1Deng-Fu Yao,Hua Jiang,Min Yao,Yue-Ming Li,Wen-Jing Gu,Yu-Cheng Shen, Li-Wei Qiu,Wei Wu,Xin-Hua Wu and Wen-Li Sai Research Center of Clinical Molecular Biology,Department of Laboratory Science,and Department of Oncology,Affiliated Hospital of Nantong University,Nantong 226001, China,Third Department of Medicine,Jiaonan People’s Hospital,Jiaonan 266400,China.Quantitative analysis of hepatic hypoxia-inducible factor-1α and its abnormal gene expression during the formation of hepatocellular carcinoma[J].Hepatobiliary & Pancreatic Diseases International,2009,8(4):407-413. 被引量:28
  • 2张燕,左国庆,汤为学.奥沙利铂对人肝癌细胞株HepG2体外增殖的影响[J].中华肝脏病杂志,2004,12(6):374-375. 被引量:40
  • 3夏曙,于世英,袁响林,付向宁.非小细胞肺癌中HIF-1α蛋白的表达与多药耐药蛋白相关性的研究[J].中华实验外科杂志,2004,21(12):1515-1517. 被引量:10
  • 4冯觉平,于世英,王亚萍,袁响林,李敏,方静.奥沙利铂对肝癌细胞HepG2生物学行为的影响[J].肿瘤,2010,30(9):753-757. 被引量:3
  • 5Shukui Qin,Yuxian Bai,Ho Yeong Lim,Sumitra Thongprasert,Yee Chao,Jia Fan,Tsai-Shen Yang,Vajarabhongsa Bhudhisawasdi,Won Ki Kang,Yu Zhou,Jee Hyun Lee,Yan Sun.Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia[J].Journal of Clinical Oncology.2013(28)
  • 6Peng Xiu,Xuesong Dong,Xiaofeng Dong,Zongzhen Xu,Huaqiang Zhu,Feng Liu,Zheng Wei,Bo Zhai,Jagat R. Kanwar,Hongchi Jiang,Jie Li,Xueying Sun.Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma[J].Cancer Sci.2013(3)
  • 7Olivier Mir,Romain Coriat,Pascaline Boudou-Rouquette,Stanislas Ropert,Jean-Philippe Durand,Anatole Cessot,Vincent Mallet,Philippe Sogni,Stanislas Chaussade,Stanislas Pol,Fran?ois Goldwasser.Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib[J].Medical Oncology.2012(4)
  • 8Alejandro Forner,Josep M Llovet,Jordi Bruix.Hepatocellular carcinoma[J].The Lancet.2012(9822)
  • 9Kai Qu,Xinsen Xu,Chang Liu,Qifei Wu,Jichao Wei,Fandi Meng,Lei Zhou,Zhixin Wang,Lei Lei,Peijun Liu.Negative regulation of transcription factor FoxM1 by p53 enhances oxaliplatin-induced senescence in hepatocellular carcinoma[J].Cancer Letters.2012
  • 10JunjiFuruse,TakujiOkusaka,ShuichiKaneko,MasatoshiKudo,KoheiNakachi,HidekiUeno,TatsuyaYamashita,KazuomiUeshima.Phase I/II study of the pharmacokinetics, safety and efficacy of S‐1 in patients with advanced hepatocellular carcinoma[J].Cancer Science.2010(12)

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部